Showing 8981-8990 of 20386 results for "".
- The Role of PPARβ/δ in Regulating Insulin Receptor Levels: New Insights for Diabetes Managementhttps://reachmd.com/news/the-role-of-ppar-in-regulating-insulin-receptor-levels-new-insights-for-diabetes-management/2471264/Recent studies have uncovered the vital role of PPARβ/δ in regulating insulin receptor levels in skeletal muscle, offering promising avenues for managing insulin resistance and type 2 diabetes. Understanding Insulin Resistance Insulin r
- This Outdated Diabetes Drug Still Has Something to Offerhttps://reachmd.com/news/this-outdated-diabetes-drug-still-has-something-to-offer/2462707/“The exosomes were just as effective in reversing insulin resistance as the drug itself but without the same side effects,” said Olefsky. “This indicates that exosomes can ultimately link obesity-related inflammation and insulin resistance to diabetes. It also tells us
- A New Type of RNA Could Revolutionize Vaccines and Cancer Treatmentshttps://reachmd.com/news/a-new-type-of-rna-could-revolutionize-vaccines-and-cancer-treatments/2468173/A New Type of RNA Could Revolutionize Vaccines and Cancer TreatmentsAn accidental discovery turned into an unexpected success, when a team of interdisciplinary researchers created a new and improved COVID vaccine It all started in the
- High Oxygen Levels Show Limited Impact on Chemoreceptor Overactivity in Type 2 Diabeteshttps://reachmd.com/news/high-oxygen-levels-show-limited-impact-on-chemoreceptor-overactivity-in-type-2-diabetes/2470799/Could manipulating oxygen levels help manage cardiovascular and metabolic disorders? Researchers from the University of Missouri sought to answer this question by exploring the role of peripheral chemoreceptors—specialized cells near the carotid artery—in conditions like high blo
- FDA Clears First Automated Device to Deliver Insulin to People with Type 2 Diabeteshttps://reachmd.com/news/fda-clears-first-automated-device-to-deliver-insulin-to-people-with-type-2-diabetes/2467971/by Robin Foster
- Largest Study of Its Kind Finds New Genetic Risk Factors for Type 2 Diabeteshttps://reachmd.com/news/largest-study-of-its-kind-finds-new-genetic-risk-factors-for-type-2-diabetes/2462322/
- Innovative Approaches to Managing Diabetic Peripheral Neuropathyhttps://reachmd.com/news/innovative-approaches-to-managing-diabetic-peripheral-neuropathy-dpn/2474554/Diabetic peripheral neuropathy (DPN) remains a prevalent and debilitating complication of diabetes, often leading to significant morbidity. Recent innovations in therapeutic strategies are offering new avenues for clinicians to enhance patient outcomes and quality of life.<
- New Target for Treating Diabetic Cardiomyopathy Identifiedhttps://reachmd.com/news/new-target-for-treating-diabetic-cardiomyopathy-identified/2468762/Advances in understanding diabetic cardiomyopathy have revealed a potential therapeutic target for a disease that currently has no specific treatments. Diabetic cardiomyopathy, a progressive heart condition that is independent of hypertension or other cardiovascular disorders, is one of th
- Topical Ruxolitinib Gel in Prurigo Nodularis: Phase I/II Trialhttps://reachmd.com/news/topical-ruxolitinib-gel-in-prurigo-nodularis-phase-iii-trial/2487677/Key Takeaways This phase I/II, randomized, double-blind, vehicle-controlled, multicenter trial in China assigned 49 adults with prurigo nodularis 2:1 to HDM3010 or vehicle across once-daily and twice-daily cohorts. Treatment-emergent events were infreq
- EMA Validates Bristol Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy for First-Line Treatment of Unresectable or Advanced HCChttps://reachmd.com/news/ema-validates-bristol-myers-squibbs-type-ii-variation-application-for-opdivo-plus-yervoy-for-first-line-treatment-of-unresectable-or-advanced-hcc/2467580/Bristol Myers Squibb announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) a